Previous Close | 176.95 |
Open | 177.02 |
Bid | 177.41 x 800 |
Ask | 177.55 x 1000 |
Day's Range | 176.85 - 180.19 |
52 Week Range | 137.65 - 207.32 |
Volume | |
Avg. Volume | 5,592,946 |
Market Cap | 313.031B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | 61.72 |
EPS (TTM) | 2.87 |
Earnings Date | Jan 31, 2025 - Feb 04, 2025 |
Forward Dividend & Yield | 6.56 (3.71%) |
Ex-Dividend Date | Jan 15, 2025 |
1y Target Est | 204.74 |
The United States market has experienced a robust performance with a 2.2% climb over the past week and an impressive 32% increase over the last 12 months, while earnings are forecast to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.